Topas raises 22m in Series B financining
Topas Therapeutics GmbH will use the 22m proceeds from a Series B Financing to advance two pipeline candidates.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1177 entries already.
Entries by Thomas Gabrielczyk
Siemens launches COVID-19 antigen lateral flow test
/in News/by Thomas GabrielczykSiemens Healthineers has launched its Clinitest Rapid COVID-19 Antigen Test in Europe, which can identify persons infected with SARS-CoV-2 in 15 minutes.
Priothera closes 30m Series A financing
/in News/by Thomas GabrielczykPriothera Ltd. wants to use 30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).
COVID-19 jab: EU signs contract with JNJ
/in News/by Thomas GabrielczykJohnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
Santhera ends development of idebenone
/in News/by Thomas GabrielczykSwiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.
Nobel Prize in Physiology for HCV pioneers
/in News/by Thomas GabrielczykThe Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric
Swiss Sophia Genetics to expand globally
/in News/by Thomas GabrielczykSwiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
EIB and EC launch circular bioeconomy fund
/in News/by Thomas GabrielczykThe European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of 250m. ·
Dewpoint Therapeutics raise $77m in Series B financing
/in News/by Thomas GabrielczykA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at 50m
/in News/by Thomas GabrielczykThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at 50m.